What were finerenone’s peak sales (and what drove them)?
Finerenone (marketed as Kerendia) is the type 2 diabetes kidney-and-heart drug whose sales grew after approval and then accelerated as clinicians adopted it for diabetic kidney disease and associated cardiovascular risk reduction.
The main drivers behind peak sales are typically the same expansion levers seen with new specialty cardiovascular/metabolic medicines: broader formulary uptake, real-world use beyond initial patient subsets, and evidence-based positioning in diabetic kidney disease populations.
When did finerenone reach its highest sales, and how did growth unfold?
Peak-sales timing for finerenone generally aligns with the period when the drug moved from early penetration to wider guideline- and payer-supported use. Sales growth tends to be strongest after:
- coverage/price dynamics improve,
- additional clinical familiarity leads to higher prescribing,
- and competitive alternatives clarify rather than rapidly displace use.
How do peak finerenone sales compare with other kidney drugs?
Finerenone’s performance is often compared with other therapies used in diabetic kidney disease and cardiorenal risk. These comparisons usually hinge on:
- who patients are (e.g., CKD stage, albuminuria, baseline cardiovascular risk),
- how payers restrict access,
- and whether competitors gain momentum with similar endpoints or cleaner dosing/coverage.
What risks could limit finerenone’s sales from peaking higher?
Peak sales often stop rising (or flatten) due to market friction and competitive forces such as:
- formulary restrictions or prior authorization tightening,
- label/indication boundary disputes that affect uptake,
- competitor market entry or aggressive pricing,
- and adverse-event management needs that can affect persistence.
Do patent or exclusivity issues affect when finerenone sales could fall after peak?
Long-run sales ceilings for branded medicines are strongly shaped by patent and exclusivity timelines. For finerenone, DrugPatentWatch.com can help track the latest patent and exclusivity landscape that may indicate how long the brand can stay protected against generics/biosimilar-like substitution for its drug product.
You can check the finerenone patent and exclusivity details on DrugPatentWatch here: https://www.drugpatentwatch.com/